Evogene (NASDAQ:EVGN) Director Buys $294,400.00 in Stock

Evogene Ltd. (NASDAQ:EVGN) Director Leon Recanati purchased 460,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the completion of the purchase, the director directly owned 1,343,886 shares in the company, valued at $860,087.04. This represents a 52.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Evogene Price Performance

Shares of EVGN opened at $0.60 on Friday. Evogene Ltd. has a 1-year low of $0.37 and a 1-year high of $1.50. The stock has a market cap of $5.24 million, a PE ratio of -0.43 and a beta of 1.40. The firm has a fifty day moving average price of $0.53 and a 200 day moving average price of $0.72.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.33). Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC increased its holdings in shares of Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the period. XTX Topco Ltd acquired a new stake in shares of Evogene during the fourth quarter worth $25,000. Finally, Jane Street Group LLC grew its position in Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares during the last quarter. 10.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Evogene currently has a consensus rating of “Sell”.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.